Homozygous Familial Hypercholesterolemia (HoFH)Symptoms, Doctors, Treatments, Advances & More
Homozygous Familial Hypercholesterolemia (HoFH) Overview
Learn About Homozygous Familial Hypercholesterolemia (HoFH)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
OHSU Hospital
Paul Duell is an Endocrinologist practicing medicine in Portland, Oregon. Dr. Duell is rated as an Elite provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Familial Hypercholesterolemia, Defective Apolipoprotein B-100, Homozygous Familial Hypercholesterolemia (HoFH), and Heterozygous Familial Hypercholesterolemia (HeFH).
Frederick Raal practices practicing medicine in Johannesburg, South Africa. Mr. Raal is rated as an Elite expert by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, and Familial Hypercholesterolemia.
Daniel Gaudet practices practicing medicine in Chicoutimi, Canada. Mr. Gaudet is rated as an Elite expert by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses High Cholesterol, Familial Hypertriglyceridemia, Familial Lipoprotein Lipase Deficiency, and Apolipoprotein C2 Deficiency.
Summary: This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE...
Summary: This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.